Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 6.2% – Still a Buy?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) shares shot up 6.2% on Thursday . The company traded as high as $1.12 and last traded at $1.1050. 75,253 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 120,683 shares. The stock had previously closed at $1.04.

Actinium Pharmaceuticals Stock Up 6.2%

The firm has a fifty day moving average of $1.33 and a 200-day moving average of $1.46. The stock has a market capitalization of $34.47 million, a price-to-earnings ratio of -0.79 and a beta of -0.30.

Institutional Trading of Actinium Pharmaceuticals

Large investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new position in shares of Actinium Pharmaceuticals in the fourth quarter valued at approximately $89,000. Renaissance Technologies LLC grew its stake in Actinium Pharmaceuticals by 35.4% in the 4th quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after acquiring an additional 102,154 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Actinium Pharmaceuticals in the 4th quarter worth approximately $96,000. AM Investment Strategies LLC acquired a new position in Actinium Pharmaceuticals in the 4th quarter valued at $40,000. Finally, Bailard Inc. purchased a new position in shares of Actinium Pharmaceuticals during the 4th quarter worth $79,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.